About Annapurna Therapeutics
Annapurna Therapeutics is a company based in Paris (France) founded in 2014 was acquired by Adverum Biotechnologies in February 2016.. Annapurna Therapeutics has raised $12 million across 1 funding round from investors including Adverum Biotechnologies, Inserm Transfert and Versant Ventures. Annapurna Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12 M (USD)
in 1 rounds
-
Latest Funding Round
$12 M (USD), Series A
Apr 15, 2014
-
Investors
Adverum Biotechnologies
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Adverum Biotechnologies
(Feb 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Annapurna Therapeutics
Annapurna Therapeutics has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series A round of $12 million completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $12.0M
-
First Round
First Round
(15 Apr 2014)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2014 | Amount | Series A - Annapurna Therapeutics | Valuation | Versant Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Annapurna Therapeutics
Annapurna Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Adverum Biotechnologies, Inserm Transfert and Versant Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Investments are directed toward early-stage healthcare companies in France.
|
Founded Year | Domain | Location | |
|
Gene therapies for ocular disorders are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Annapurna Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Annapurna Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Annapurna Therapeutics Comparisons
Competitors of Annapurna Therapeutics
Annapurna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Annapurna Therapeutics
When was Annapurna Therapeutics founded?
Annapurna Therapeutics was founded in 2014.
Where is Annapurna Therapeutics located?
Annapurna Therapeutics is headquartered in Paris, France.
Is Annapurna Therapeutics a funded company?
Annapurna Therapeutics is a funded company, having raised a total of $12M across 1 funding round to date. The company's 1st funding round was a Series A of $12M, raised on Apr 15, 2014.
What does Annapurna Therapeutics do?
Annapurna Therapeutics was founded in 2014 and is based in Paris, France. Adeno-associated virus (AAV) mediated gene therapies for rare diseases are developed, with emphasis on cardiomyopathy linked to Friedreichs ataxia and severe allergies. Pipeline programs are directed toward alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), and related conditions in the biotechnology sector. Operations center on advancing these therapeutic candidates through research and development.
Who are the top competitors of Annapurna Therapeutics?
Annapurna Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Who are Annapurna Therapeutics's investors?
Annapurna Therapeutics has 3 investors. Key investors include Adverum Biotechnologies, Inserm Transfert, and Versant Ventures.